TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Perez, Oscar
Abrégé
The present invention provides a single homologous recombination vector comprising components of the CRISPR-Cas system to insert transgenic DNA in cells. This vector shortens the production time and allow for easy generation of genetically modified cells. The invention allows the user to test multiple tags and to generate homozygous modified cell line using the homologous recombination vector. The invention can be used to generate knockout cells, to generate cell lines with knockin genes, to generate cell lines with point mutations, to generate cell lines for drug screening against any target, to create transgenic animals.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Wright, William Geoffrey
Abrégé
A method of assessing the balance impairment of a subject includes the steps of presenting the subject with a static scene on a display, collecting a first set of orientation measurements, presenting the subject with an unstable scene on a display, collecting a second set of orientation measurements, storing the first and second sets of orientation measurements on a computing device, referenced to a set of time indices, and calculating a balance score for the subject by comparing the second set of orientation measurements with the first set of orientation measurements. A system for assessing the balance impairment of a subject is also disclosed.
Temple University-Of The Commonwealth System of Higher Education (USA)
ThirdLaw Molecular Inc. (USA)
Inventeur(s)
Schafmeister, Christian
Northrup, Justin
Abrégé
The present invention provides novel intermediates and other compounds prepared using compounds of Formula I. These novel compounds include spiroligomers that have particular significance in the peptide industry. The processes described herein provide products that are produced in high yields in high purities and, thus, are highly efficient.
C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
4.
CRISPR METHODS FOR CORRECTING BAG3 GENE MUTATIONS IN VIVO
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Chen, Chen
Liao, Shuren
Liu, Hong
Abrégé
Compositions include gene-editing complexes for the treatment of myopathies, cancer and neurodegenerative diseases. Specifically, the disclosure provides methods of identifying in a subject's biological sample, ‘at least one Bcl2-associated anthanogene 3 (BAGS) genetic mutation as compared to a control BAGS nucleic acid sequence, and administering to the subject a therapeutically effective amount of a gene-editing complex, wherein the gene-editing complex corrects the bag3 mutation to a wild-type bag3, thereby, treating the subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Gerstenhaber, Jonathan
Erkmen, Kadir
Licata, Joseph
Pathak, Sami
Graves, Erin
Abrégé
A surgical guide includes a base having a first body having a proximal opening, a distal opening and an internal chamber therebetween. The proximal opening has a plurality of recesses disposed along an inner perimeter of the proximal opening. A first insert includes a second body having a proximal end, a distal end, and a channel extending therebetween. The proximal end has a plurality of protrusions disposed along an outer perimeter and configured to interface with the plurality of recesses. The channel is angled away from a central vertical axis by a first angle. A surgical guide kit and a method for guiding an external ventricular drain are also described.
A61B 90/11 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures pour la chirurgie stéréotaxique, p. ex. système stéréotaxique à cadre avec des guides pour aiguilles ou instruments, p. ex. des glissières courbes ou des articulations à rotule
6.
Use of short chain fatty acids for the treatment and prevention of diseases and disorders
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Arzumanyan, Alla
Spector, Ira C.
Feitelson, Mark A.
Abrégé
The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Hu, Wenhui
Wollebo, Hassen
Abrégé
The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising an CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Temple University of the Commonwealth System of Higher Education (USA)
University of Toledo (USA)
Inventeur(s)
Abou-Gharbia, Magid
Childers, Wayne
Sari, Youssef
Abrégé
A method is provided for treating or preventing alcohol dependence and/or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):
A method is provided for treating or preventing alcohol dependence and/or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):
A method is provided for treating or preventing alcohol dependence and/or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):
or a hydrates, a solvate, a pharmaceutically acceptable salt, a prodrug, or a complex thereof to a subject in need thereof. For example, (3S, 4R)-3-((R)-(1-hydroxy-ethyl)-4-((R)-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-azetidin-2-one (MC-100093) is an exemplary compound. The composition can be used to prevent or treat alcohol dependence, attenuate alteration in glutamate transporters, reduce alcohol associated neuroinflammation, and treat or prevent alcohol associated fatty liver diseases.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Wu, Sheng
Abrégé
Women with polycystic ovary syndrome (PCOS) are predicted to have a higher risk for developing nonalcoholic fatty liver disease than normal women associated with insulin resistance and hypertrophy of adipose tissue. This invention provides improved compositions and methods for the treatment of liver disease in women including in women with PCOS.
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
10.
Use of short chain fatty acids for the treatment and prevention of diseases and disorders
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Arzumanyan, Alla
Spector, Ira C.
Feitelson, Mark A.
Abrégé
The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
Temple University-Of The Commonwealth system of Higher Education (USA)
Inventeur(s)
Baharlou, Sogol M.
Gerstenhaber, Jonathan A.
Har-El, Yah-El H.
Lelkes, Peter I.
Abrégé
The present invention provides portable devices and systems for electrofocused blow spinning, and methods for using the same. The devices of the invention are convenient to carry and use and are able to acrodynamically spin a variety of materials in a mobile setting.
D04H 1/728 - Non-tissés formés uniquement ou principalement de fibres coupées ou autres fibres similaires relativement courtes caractérisés par la méthode de formation des voiles ou couches, p. ex. par la réorientation des fibres les fibres étant disposées au hasard par électrofilage
D01D 5/00 - Formation des filaments, fils ou similaires
D01D 5/14 - Méthodes de filage par étirage par circulation de fluides provoquant l'étirage
D01F 1/10 - Autres agents modifiant les propriétés de ces filaments
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Zhang, Yi
He, Shan
Abrégé
The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Strongin, Daniel
Dunuweera, Shashiprabha Punyakanth
Valentine, Ann
Cerkez, Elizabeth
Abrégé
The present invention provides a composition comprising a Ferritin-metal nanoparticle bioconjugate, wherein the Ferritin-metal nanoparticle bioconjugate comprises at least one metal nanoparticle and at least one Ferritin or a variant or a fragment thereof conjugated to the at least one metal nanoparticle; and wherein the Ferritin-metal nanoparticle bioconjugate specifically targets at least one cell expressing a transferrin receptor 1 (TfR1), and methods of making and use thereof.
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Canney, Daniel J.
Blass, Benjamin E.
Gao, Rong
Abou-Gharbia, Magid
Abrégé
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 307/33 - Atomes d'oxygène en position 2, l'atome d'oxygène étant sous la forme céto ou énol non substituée
C07D 307/94 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en spiro avec des carbocycles ou avec des systèmes carbocycliques, p. ex. griséofulvines
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
15.
CHIMERIC CAPSID RECOMBINANT ADENO-ASSOCIATED VIRUS WITH BBB PENETRATION AND MICROGLIA TARGETING (AAV-BM)
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Hu, Wenhui
Abrégé
Compositions that target microglia-related diseases such as infectious diseases (e.g. HIV), neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, Huntington's diseases), neurodevelopmental disorders (e.g. autism, intellectual disability) and CNS injury (e.g. TBI, SCI), include gene editing complexes. Novel AAV-BM serotypes that can cross the blood-brain barrier and transduce microglia, and package nucleic acid sequences, inclusive of, gene-editing complexes, shRNAs, sgRNAs, miRNAs and lncRNAs are utilized in the treatment of neurological diseases.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Feitelson, Mark A.
Abrégé
The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Patil, Chetan, A.
Dumont, Alex
Harrison, Brandon
Arefin, Shahriar
Abrégé
A 2D image sensor system for optical measurements of physiological parameters through a patient's skin using spatially resolved diffuse reflectance. The system includes a 2D image sensor adapted to be placed near/against the skin with at least three wavelength-dependent spectral channels and a field of view (FOV) with multiple spatial regions of interest (ROI). A source directs light onto the skin at a distance offset from the FOV. A detector receives light reflected from the skin and collects a 2D map of the entire reflectance spatial decay profile characteristic of the skin in different detector channels. A selector identifies multiple ROI that can be uniquely positioned in each spectral channel and/or partially overlapping in the 2D reflectance spatial decay map as the elements of a multivariate regression model to approximate a physiological parameter. The increased dimensionality of the system outputs improves measurement accuracy and reduces bias in confounding optical factors.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
G01J 3/42 - Spectrométrie d'absorptionSpectrométrie à double faisceauSpectrométrie par scintillementSpectrométrie par réflexion
G01N 21/49 - Dispersion, c.-à-d. réflexion diffuse dans un corps ou dans un fluide
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Kaminski, Rafal
Abrégé
Compositions include CRISPR-associated endonuclease, and one or more isolated nucleic acid sequences encoding gRNAs, wherein each gRNA is complementary to a target sequence in a retroviral genome. At least one endonuclease targets a Mannosyl Oligosaccharide Glucosidase (MOGS).
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Rappaport, Jay
Vakili, Sarah
Abrégé
The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Blass, Benjamin E.
Canney, Daniel J.
Blattner, Kevin M.
Abrégé
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Blass, Benjamin E.
Canney, Daniel J.
Blattner, Kevin M.
Abrégé
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Kamel, Ihab
Abrégé
The present invention provides an endoluminal medication delivery device and method configured to allow immediate, repeated, precise, and controlled circumferential medication delivery to the interface between the device and the compressed surrounding tissue lining the lumen (e.g., Mucosa/mucous membrane).
West Virginia University Board of Governors on behalf of West Virginia University (USA)
Temple University-Of the Commonwealth System of Higher Education (USA)
University of Pittsburgh-Of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Barnett, John B.
Geldenhuys, Werner
Soboloff, Jonathan
Blair, Harry Colbert
Mccall, Jamie
Abrégé
A method of inhibiting the development of osteoclasts in patients having multiple myeloma comprising administering to a patient having multiple myeloma a therapeutically effective amount of N-Methyl-dichloropropionaniline (i.e. also known as ELP-004) for inhibiting the development of osteoclasts. The method includes wherein said N-Methyl-dichloropropionaniline is administered to said patient in a pharmaceutically acceptable vehicle.
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Abrégé
The present disclosure relates to compositions and methods for the inhibition of the infectivity of a herpesvirus. The present disclosure relates in general to compositions and methods of treating or eradicating Herpes Simplex virus infections. The disclosure relates in particular to targeting of Herpes Simplex virus genes by gene editing complexes.
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Kaminski, Rafal
Abrégé
Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Smutzer, Gregory S.
Lee, Kevin
Patel, Dhruti
Abrégé
The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
27.
SURFACE COATINGS FOR ENHANCED SUBSTRATE PROPERTIES
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Mohsin, Sadia
Houser, Steven
Kubo, Hajime
Abrégé
Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
29.
TREATMENT OF SKIN DISORDERS WITH SHORT CHAIN FATTY ACIDS
TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Arzumanyan, Alla
Feitelson, Mark, A.
Spector, Ira
Abrégé
The present disclosure describes methods of treating a condition comprising administering a pharmaceutical composition comprising at least one short chain fatty acid (SCFA). The disclosed methods can be used to treat a skin disorder or an autoimmune disorder.
TEMPLE UNIVERSITY- of THE COMMONWEALTH SYSTEM of HIGHER EDUCATION (USA)
Inventeur(s)
Tehrani, Rouzbeh Afsarmanesh
Alimohammadi, Farbod
Abrégé
A novel method of synthesizing polyacrylic beads, comprising the steps of suspending a monomer and a cross-linking agent in a solution, heating the solution in a microwave reactor, cooling the solution, and collecting the polyacrylic beads. The polyacrylic beads can be used in to remove solutes from various solutions, including blood, porcine blood, dialysate, serum, contaminated water, wastewater, and combinations thereof.
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
C08F 2/46 - Polymérisation amorcée par énergie ondulatoire ou par rayonnement corpusculaire
C08F 220/06 - Acide acryliqueAcide méthacryliqueLeurs sels métalliques ou leurs sels d'ammonium
C08J 3/28 - Traitement par ondes énergétiques ou par rayonnement de particules
A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c.-à-d. hémofiltration, diafiltration
A61P 13/00 - Médicaments pour le traitement des troubles du système urinaire
C08F 8/42 - Introduction d'atomes métalliques ou de groupes contenant des atomes métalliques
C08J 3/07 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans un milieux aqueux à partir de solutions de polymères
31.
DEVICES AND METHODS TO REDUCE AIR POLLUTION AND GLOBAL WARMING
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Tao, Rongjia
Xu, Xiaojun
Chen, Zhi
Abrégé
A device for capturing pollution particles from a fluid is disclosed. The device includes a chamber defining a fluid pathway through which the fluid travels from an inlet, through an interior, and toward. A filter is positioned within the interior of the chamber. The filter includes one or more pairs of flat metal electrodes positioned opposite one another, and the opposed pair of electrodes form at least one channel in the fluid pathway such that a non-laminar flow of fluid having pollution particles which move adjacent to the electrodes flows from a first end of the at least one channel to a second end of the at least one channel. A power source is coupled to the filter and produces an electric field oriented perpendicular to a direction of the non-laminar flow of fluid. The electric field has a strength sufficient to polarize pollution particles in the fluid.
B03C 3/09 - Installations alimentées en électricité de l'extérieur du type par voie sèche caractérisées par la présence d'électrodes planes fixes, les surfaces planes étant perpendiculaires au courant de gaz
F24F 8/192 - Traitement, p. ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p. ex. par filtrage par des moyens électriques, p. ex. en appliquant des champs électrostatiques ou de la haute tension
B01D 46/10 - Séparateurs de particules utilisant des plaques, des feuilles ou des tampons filtrants à surface plane, p. ex. appareils de précipitation de poussières
B01D 46/24 - Séparateurs de particules utilisant des corps filtrants creux et rigides, p. ex. appareils de précipitation de poussières
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
B03C 3/34 - Parties constitutives ou accessoires, ou leur fonctionnement
B03C 3/38 - Postes de chargement ou d'ionisation des particules, p. ex. utilisant des décharges électriques, des radiations radioactives ou des flammes
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Burris, Scott, C.
Grunwald, Heidi
Abrégé
An artificial intelligence (Al)-based method for textual identification and feature generation. The method includes: defining a scope including type, time, and geographic dimensions of texts to be analyzed; collecting, identifying, and coding using a coding protocol selected features of the texts using a pre-defined research procedure and feature set; creating a corpus of machine-readable data and metadata in a software database that includes a scraping tool for searching the worldwide web for text instances and a corpus of text types; interfacing with the software to train an Al assist tool and validate its results; and using the Al assist tool to identify the particular text type and apply the coding protocol to create new and update existing data and metadata. Also provided are a related system and at least one computer-readable non-transitory storage media embodying software.
Temple University - Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Burris, Scott C.
Grunwald, Heidi
Abrégé
An artificial intelligence (AI)-based method for textual identification and feature generation. The method includes: defining a scope including type, time, and geographic dimensions of texts to be analyzed; collecting, identifying, and coding using a coding protocol selected features of the texts using a pre-defined research procedure and feature set; creating a corpus of machine-readable data and metadata in a software database that includes a scraping tool for searching the worldwide web for text instances and a corpus of text types; interfacing with the software to train an AI assist tool and validate its results; and using the AI assist tool to identify the particular text type and apply the coding protocol to create new and update existing data and metadata. Also provided are a related system and at least one computer-readable non-transitory storage media embodying software.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Li, Shuxin
Abrégé
The present invention generally relates to engineered adeno-associated viral (AAV) vectors capable of traversing the blood-brain barrier and transducing specific neural cells with high efficiency. The present invention also relates to methods of producing engineered AAV vectors and treating diseases and disorders associated with neural cell damage and degeneration.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
35.
METHODS OF TREATING OR PREVENTING LIVER DISEASES OR DISORDERS
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Arzumanyan, Alla
Feitelson, Mark, A.
Spector, Ira
Abrégé
The invention relates to compositions and methods that include short chain fatty acids (SCFAs), such as various butyrate and acetate, in combination with an antioxidant, such as Vitamin E, for the treatment or prevention of liver diseases or disorders, such as a nonalcoholic fatty liver disease (NAFLD), nonalcoholic sieatohepatitis (NASH), fibrosis, and other similar diseases or disorders.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61K 31/4738 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Liu, Haijun
Ray, Subhrodeep, Sushanta
Abrégé
A sound barrier device, comprising: a first panel having a plurality of perforations; a second panel with no perforations; and a connector connecting the first and second panels and forming an air gap between the first and second panels. The air gap may be formed by attaching the first and second panels to one or more frames, or by placing spacers between the first and second panels.
E04B 1/82 - Isolation thermique ou acoustique, absorption ou réflexion de la chaleur ou du sonAutres méthodes de construction procurant des conditions thermiques ou acoustiques favorables, p. ex. par accumulation de chaleur à l'intérieur des murs spécifiquement relatives au son uniquement
B32B 3/12 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche discontinue, c.-à-d. soit continue et percée de trous, soit réellement constituée d'éléments individuels caractérisés par une couche d'alvéoles disposées régulièrement, soit formant corps unique dans un tout, soit structurées individuellement ou par assemblage de bandes indépendantes, p. ex. structures en nids d'abeilles
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Hu, Wenhui
Abrégé
A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Ren, Shenqiang
Percec, Simona
Zhang, Zhuolei
Abrégé
A method of fabricating a polymer composite material by mixing a polymer material with a planar material, depositing the mixture on a substrate, and stretching the resulting thin film, is described. Polymer composite materials produced using said method and ballistic resistant materials comprising said polymer composite materials are also described.
B29C 41/00 - Façonnage par revêtement d'un moule, noyau ou autre support, c.-à-d. par dépôt de la matière à mouler et démoulage de l'objet forméAppareils à cet effet
B29C 55/00 - Façonnage par étirage, p. ex. étirage à travers une matriceAppareils à cet effet
B29C 55/04 - Façonnage par étirage, p. ex. étirage à travers une matriceAppareils à cet effet de plaques ou de feuilles suivant un seul axe, p. ex. étirage oblique
B29C 55/18 - Façonnage par étirage, p. ex. étirage à travers une matriceAppareils à cet effet de plaques ou de feuilles par serrage entre des surfaces, p. ex. des rouleaux
C08J 3/21 - Formation de mélanges de polymères avec des additifs, p. ex. coloration en présence d'une phase liquide le polymère étant prémélangé avec une phase liquide
C08K 7/00 - Emploi d'ingrédients caractérisés par leur forme
F41H 5/04 - Structure des plaques composées de plus d'une couche
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (USA)
Inventeur(s)
Gokcen, Eric
Gokcen, Cem
Abrégé
An intravenous needle insertion device is described. The device includes a body having a front end, a back end, a bottom surface and a top surface sloping downward toward the front end. The device further includes a vein trough recessed within the bottom surface of the body, a needle trough recessed within the top surface of the body, a puncture window at the front end of the body, where the vein trough and the needle trough both lead into the puncture window.
A61M 5/42 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour insensibiliser la peau, pour soulever la peau en vue de faciliter la piqûre ou pour localiser le point du corps où la piqûre doit être effectuée
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
42.
BAG 3 METHODS AND USES FOR TREATMENT OF CARDIAC AMYLOIDOSIS
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Temple University of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Andreasyan, Haykazuni
Diloyan, Oleksandr
Abrégé
Apparatus for increasing burning efficiency including a bottom shell having a plate defining a first opening for receiving a fuel source and a side wall extending in an upward direction. The side wall has a first side wall end coupled to the plate and a second side wall end spaced from the first side wall end in the upward direction. Additionally, the apparatus includes a top shell having inner and outer walls defining a cavity for receiving the second side wall end of the side wall of the bottom shell. The inner wall has a first inner end and a second inner end and the outer wall has a first outer end and a second outer end. The first inner end is coupled to the first outer end and the second inner end is spaced from the second outer end to receive at least the second side wall end.
F23D 14/06 - Brûleurs à gaz avec prémélangeurs, c.-à-d. dans lesquels le combustible gazeux est mélangé à l'air de combustion en amont de la zone de combustion du type à induction, p. ex. becs Bunsen avec les orifices de sortie disposés radialement dans la tête du brûleur
F23D 14/58 - Buses caractérisés par la forme ou la disposition de l'orifice ou des orifices des buses, p. ex. en couronne
44.
FLUID PURIFICATION COMPOSITIONS AND METHODS OF FLUID PURIFICATION USING THE SAME
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Tehrani, Rouzbeh
Abrégé
Described herein is a composition comprising porous particles, wherein the porous particles comprise an organic polymer and further comprise functional groups that selectively and reversibly bind blood components. Also described herein is method of dispersing a medical composition in a filtration unit, the method comprising the steps of: providing a vessel comprising a medical composition: securing the vessel to a filtration unit; and depositing the composition into the filtration unit; wherein the medical composition comprises porous particles comprising at least one organic polymer; the filtration unit comprises a filtration membrane having hollow fiber pores; and the average diameter of the porous particles is larger than the hollow fiber pores of the filtration membrane. Also described herein is a method of synthesizing polymer beads.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
Temple University-Of The Commonwealth System of Higher Education (USA)
Thrombolex, Inc. (USA)
Inventeur(s)
Bashir, Riyaz
Green, Nicholas A.
Abrégé
An infusion catheter has an elongate flexible shaft including a wall and a lumen extending between a proximal end and a distal end. The catheter also has a sealing member within the shaft lumen including a wall and a lumen. The catheter also has a slidable, retractable elongate central axis member extending through the shaft and sealing member lumens connected to an end cap. The catheter also has a plurality of eluting arms extending radially around the central axis member, including lumens fluidly connected to the shaft lumen and the distal end cap. A method for treating a thrombus is also disclosed.
A61B 17/221 - Dispositifs de préhension des calculs en forme de boucles ou de paniers
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
Temple University-Of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Soboloff, Jonathan
Zaidi, M. Raza
Gross, Scott
Elrod, John
Abrégé
The invention comprises methods for treating diseases or disorders associated with reduced levels of Ca2+ signaling, including melanoma and other cancers.
West Virginia University Board of Governors on Behalf of West Virginia University (USA)
Temple University-Of the Commonwealth System of Higher Education (USA)
University of Pittsburgh-Of the Commonwealth System of Higher Education (USA)
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Barnett, John B.
Geldenhuys, Werner
Soboloff, Jonathan
Blair, Harry C.
Abrégé
A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
48.
METHODS FOR EARLY DIAGNOSIS AND TREATMENT OF OPEN NEURAL TUBE DEFECTS
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Krynska, Barbara
Abrégé
The present invention relates to the discovery that various proteins are enriched in the amniotic fluid of fetuses with open neural tube defects (NTDs). The invention includes methods for the diagnosis of open NTD based upon the levels and /or differential patterns of neurocan and phosphacan in a sample of the amniotic fluid or other bodily fluid of a subject.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 38/00 - Préparations médicinales contenant des peptides
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Feitelson, Mark A.
Arzumanyan, Alla
Spector, Ira
Abrégé
The present disclosure describes compositions and methods for treating hepatitis B virus-associated hepatocellular carcinoma. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters the expression of host genes and the activity of multiple signal transduction pathways. Short chain fatty acids can be used to delay or block the progression of chronic liver disease to HCC by targeting functions associated with HBx.
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Liao, Shuren
Sariyer, Ilker K.
Abrégé
Compositions for prevention or treatment for the SARS family of coronaviruses, e.g., SARS-CoV-2 and SARS-OC43 (common cold virus), include non-nucleoside reverse transcriptase inhibitors (NNRTI), such as rilpivirine, and nucleoside-analogue antiviral agents, such as remdesivir.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61P 31/14 - Antiviraux pour le traitement des virus ARN
52.
METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Feitelson, Mark
Arzumanyan, Alla
Spector, Lra
Abrégé
Disclosed herein are methods and pharmaceutical compositions to treat systemic inflammatory response syndrome. In some embodiments, a pharmaceutical composition disclosed herein comprises at least two short chain fatty acids or pharmaceutically-acceptable salts thereof in a ratio of at least 4:1. In some embodiments, administering a pharmaceutical composition of the disclosure reduces a level of a cytokine in the subject.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Dai, Hai-Lung
Sharifian, Mohammad
Wilhelm, Michael
Abrégé
The present invention generally relates to improved methods for characterizing the cell wall complex composition of a bacterial specimen via differential transport kinetics of a small molecule. The present invention also relates to improved and automated methods for Gram differentiation of a bacterial specimen using nonlinear optical techniques.
G01N 21/63 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité optiquement
54.
Antisite Defect Qubits in Monolayer Transition Metal Dichalcogenides
Temple University-Of The Commonwealth System Of Higher Education (USA)
Inventeur(s)
Tsai, Jeng-Yuan
Pan, Jinbo
Lin, Hsin
Bansil, Arun
Yan, Qimin
Abrégé
Anion antisite defects in monolayer Transition Metal Dichalcogenide (TMD) systems are here identified as two-dimen-sional solid-state defect qubits. The proposed antisites in these TMDs host paramagnetic triplet ground states with flexible level splitting. A viable transition loop between the triplet and singlet defect states is demonstrated, including optical excitations/relaxations and nonradiative decay paths for the antisites as qubits. A complete set of qubit operational processes, including initialization, manipulation, and readout, is delineated.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
H01L 29/66 - Types de dispositifs semi-conducteurs
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Feldman, Arthur M.
Cheung, Joseph Y.
Khalili, Kamel
Abrégé
The invention provides methods of treating ischemia/reperfusion injury in a subject. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide in ischemic tissue. The invention also provides methods of treating a subject at risk of ischemia/reperfusion injury. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide. In the invention methods, in one example, a pharmaceutical composition comprises a nucleic acid encoding BAG3 polypeptide.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Timnak, Azadeh
Lelkes, Peter I.
Har-El, Yah-El H.
Abrégé
The present invention provides porous biomimetic scaffolds and methods for making the same. The scaffolds have graded pore sizes for enhanced cell penetration. The scaffolds are useful for wound regeneration by facilitating cell penetration into the scaffold interior and due to their inherent immunomodulatory effects. The scaffolds have tissue modeling specification by mimicking the inherent stratified structure of certain tissues.
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Feldman, Arthur M.
Myers, Valerie
Abrégé
BAG3 protein is used in the treatment of, for example, is Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington disease, Lewy body disease, vascular dementia, mixed dementia and Traumatic Brain Injury, for example, complicated by Chronic Traumatic Encephalopathy (CTE). Therapeutically effective BAG3 compositions, BAG3 uses and BAG3 methods of treatment are described.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Soudbakhsh, Damoon
Sahraei, Elham
Derakhshan, Mohsen
Abrégé
A system for detecting mechanically damaged energy storage devices comprises an analyzer, a battery electrically connected to the analyzer, and a computing system communicatively connected to the analyzer and/or battery. A method for detecting mechanically damaged energy storage devices comprises applying an input at a range of frequencies to an energy storage device, measuring an output from the energy storage device, performing Electrochemical Impedance Spectroscopy (EIS) with Dynamic Relaxation Time (DRT) to calculate an impedance spectrum of the energy storage device, and modeling the energy storage device based on the impedance spectrum to identify if the energy storage device is mechanically damaged.
G01R 31/392 - Détermination du vieillissement ou de la dégradation de la batterie, p. ex. état de santé
G01R 31/367 - Logiciels à cet effet, p. ex. pour le test des batteries en utilisant une modélisation ou des tables de correspondance
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01R 31/389 - Mesure de l’impédance interne, de la conductance interne ou des variables similaires
G01R 31/396 - Acquisition ou traitement de données pour le test ou la surveillance d’éléments particuliers ou de groupes particuliers d’éléments dans une batterie
61.
RNA GUIDED COMPOSITIONS FOR PREVENTING AND TREATING HEPATITIS B VIRUS INFECTIONS
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Wollebo, Hassen
Abrégé
Compositions that specifically cleave target sequences in Hepadnaviridae, for example Hepatitis B virus (HBV) include nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in HBV. These compositions are administered to a subject for eradicating an infection, latent or otherwise, or at risk for contracting HBV infection.
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHTER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Wollebo, Hassen S.
Abrégé
Compositions which specifically target Human T cell leukemia virus (HTLV) coding sequences and other essential protein sequences, induce mutations and/or deletions in the viral DNA, rendering the virus unable to undergo replication and less likely to infect other cells, thus halting the viral life cycle and viral propagation and halting cellular transformation induced by the virus.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Schafmeister, Christian
Northrup, Justin
Abrégé
The present invention provides novel intermediates and other compounds prepared using compounds of Formula I. These novel compounds include spiroligomers that have particular significance in the peptide industry. The processes described herein provide products that are produced in high yields in high purities and, thus, are highly efficient.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
65.
COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REGENERATION
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Kishore, Raj
Magadum, Ajit
Abrégé
The present invention generally relates to novel compositions and methods for regenerating damaged cardiac tissue. In some embodiments, the invention comprises activators of phosphor-serine aminotransferase (PSAT1) and methods of use thereof for the treatment of damaged cardiac tissue following myocardial infarction.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Schafmeister, Christian
Northrup, Justin
Abrégé
The present invention provides novel intermediates and other compounds prepared using compounds of Formula I. These novel compounds include spiroligomers that have particular significance in the peptide industry. The processes described herein provide products that are produced in high yields in high purities and, thus, are highly efficient.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
67.
BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION
Temple University of the Commonwealth System of Higher Education (USA)
Loyola University of Chicago (USA)
Inventeur(s)
Feldman, Arthur M.
Kirk, Jonathan
Abrégé
Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/− had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Chen, Chen
Liao, Shuren
Liu, Hong
Abrégé
Compositions include gene-editing complexes for the treatment of myopathies, cancer and neurodegenerative diseases. Specifically, the disclosure provides methods of identifying in a subject's biological sample, 'at least one Bcl2-associated anthanogene 3 (BAGS) genetic mutation as compared to a control BAGS nucleic acid sequence, and administering to the subject a therapeutically effective amount of a gene-editing complex, wherein the gene-editing complex corrects the bag3 mutation to a wild-type bag3, thereby, treating the subject.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
69.
GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY
Temple University of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Malcolm, Thomas
Kohn, Kenneth I.
Abrégé
A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Temple University-Of The Commonwealth Systemof Higher Education (USA)
Inventeur(s)
Percec, Simona
Celli, Jacob
Ren, Fei
Abrégé
Polymer composites may be made by providing a first polymer material; treating the first polymer material; providing a second polymer material; and pressing the first polymer material and the second polymer material. The polymer composites may be incorporated into ballistic resistant materials and soft armor articles.
B32B 27/12 - Produits stratifiés composés essentiellement de résine synthétique adjacente à une couche fibreuse ou filamenteuse
B32B 27/16 - Produits stratifiés composés essentiellement de résine synthétique spécialement traitée, p. ex. irradiée
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
B32B 27/34 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyamides
B32B 5/02 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par les caractéristiques de structure d'une couche comprenant des fibres ou des filaments
C08L 77/10 - Polyamides dérivés de groupes amino et carboxyle liés aromatiquement soit d'acides aminocarboxyliques, soit de polyamines et d'acides polycarboxyliques
C08L 23/26 - Compositions contenant des homopolymères ou des copolymères d'hydrocarbures aliphatiques non saturés ne possédant qu'une seule liaison double carbone-carboneCompositions contenant des dérivés de tels polymères modifiées par post-traitement chimique
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Weprin, Samuel Alex
Noel, John
Eun, Daniel D.
Abrégé
A magnetometer-based metal detection device and methods of use are described. The device includes a proximal portion, a central body and a distal portion, and at least one magnetometer positioned within or on the distal portion. The at least one magnetometer includes at least one sensor capable of sensing a magnetic field in three orthogonal axes. Also described is a method of calibrating the device to achieve rotational invariance, and a method of determining a directionality or directional line along which a target metal object lies.
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Kaminski, Rafal
Burdo, Tricia
Abrégé
Migration of HIV-1 infected monocytes across the endothelial barrier plays an essential role in establishing and maintenance of viral reservoir in the brain and leads to neuroinflammation, neuronal damage, and subsequent HIV-induced central nervous system (CNS) dysfunction. These processes continue despite antiretroviral therapy (ART) due to limited pharmacological permeability of the blood-brain barrier, the presence of residual viral replication, and the reactivation of latent viruses. Compositions comprising Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonucleases targeted to activated leukocytes cell adhesion molecule (ALCAM/CD166), chemotactic recruitment (CCR2/5), adhesion to the endothelium (ALCAM) and junctional diapedesis (JAM-A) achieves maximum repression of leukocyte transmigration and block of the spread of the virus to different tissues and organs.
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Abrégé
Compositions and methods are provided for Tat-inducible expression of a CRISPR-associated endonuclease by a truncated HIV LTR promoter containing at least a core region and a TAR region of a HIV LTR promoter. The compositions may be used as a therapeutic treatment for the treatment and/or prevention of HIV.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Temple University-of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Hu, Wenhui
Abrégé
A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-I proviral genome, eradicating the HIV-I proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
(S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Merali, Salim
Childers, Wayne E.
Barrero, Carlos
Morton, George C.
Rico, Mario Cesar
Abrégé
(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
76.
Epiprinter Technology and Methods of Use for Detecting Biomolecules
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Nicholson, Allen
Stopar, Alex
Castronovo, Matteo
Abrégé
The invention relates to compositions and methods to detect hybrids with high sensitivity and selectivity in order to assess cell, tissue and organism function in both health and disease. The invention described herein, termed epiprinter, is a functionally versatile molecular entity that can detect RNA-DNA hybrids with potentially high sensitivity and selectivity.
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
Temple University - of The Commonwealth System of higher Education (USA)
Inventeur(s)
Khalili, Kamel
Hassen, Wollebo
Abrégé
Compositions that specifically cleave target sequences in Herpesviridae, for example Varicella zoster virus (VZV) include nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in VZV. These compositions are administered to a subject for treating an infection or at risk for contracting a VZV infection.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, providing courses of instruction at the undergraduate, graduate, and post-graduate level; Organizing and conducting college sport competitions and athletic events
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, providing courses of instruction at the undergraduate, graduate, and post-graduate level; Organizing and conducting college sport competitions and athletic events
82.
LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Wang, Rongsheng E.
Islam, Md Shafiqul
Lyu, Zhigang
Zhao, Yue
Buuh, Zakey Yusuf
Abrégé
This invention provides compositions comprising linked amino acid sequences, pharmaceutical compositions comprising linked amino acid sequences, and methods of making thereof. This invention also provides methods of delivering said compositions to subjects and methods of treating various disorders and diseases using the said compositions.
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
83.
BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Feldman, Arthur M.
Kirk, Jonathan
Abrégé
Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/- had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
84.
BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
LOYOLA UNIVERSITY OF CHICAGO (USA)
Inventeur(s)
Feldman, Arthur M.
Kirk, Jonathan
Abrégé
Bag3 is a multifunctional protein expressed predominantly in the heart, the skeletal muscle, the central nervous system and in many cancers. Although BAG3 was cloned only a decade ago, studies have shown that genetic variants, particularly those that result in haplo-insufficiency, can lead to severe left ventricular dysfunction; however, the full mechanisms responsible have remained obscure. To obviate the influence of heart failure itself on the biology of Bag3, ransgenic mice harboring a single allele knock-out were studied between 8 and 10 weeks of age before any obvious signs of heart failure were evident. The results were surprising and informative. First, it was found that despite a normal phenotype, young Bag3+/- had marked changes in the proteome that were characterized by changes in proteins associated with metabolism and apoptosis. Consistent with this finding, a decrease in the levels of critical proteins charged with maintaining the mitochondrial membrane potential was observed. It was also found that young mice shifted from a balance between the extrinsic and intrinsic pathways of apoptosis. However, in the presence of stress and the absence of Bag3 there was a shift from a balanced to an extrinsic dominant system (cleaved caspase 8). The diverse array of critical pathways regulated by Bag3 suggests a more important role especially during stress and that this role might include serving as an intracellular glue that holds proteins where they can be most effective rather than having them meet accidentally.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Temple University-Of The Commonwealth System of Higher Education (USA)
Praeventix, LLC (USA)
Inventeur(s)
Canney, Daniel J.
Blass, Benjamin E.
Blattner, Kevin M.
Pippin, Douglas A.
Abrégé
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
C07D 491/107 - Systèmes condensés en spiro avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 295/073 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'halogènes ou des radicaux nitro avec les atomes d'azote du cycle et les substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
C07F 7/10 - Composés comportant une ou plusieurs liaisons C—Si azotés
C07D 309/08 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 221/00 - Composés hétérocycliques contenant des cycles à six chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle, non prévus par les groupes
TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Shi, Justin, Y.
Abrégé
Systems and methods are provided for a virtual network storage as a transaction pool of a transactional application. In particular, the virtual network storage includes a set of gateway servers that form unidirectional virtual ring as a virtual single-system image of an Active Content Addressable Network (AC AN). Each gateway server manages a partition of a database by driving replicated database servers, in a shifted mirror fashion. The ACAN may represent a transaction pool for processing transactions of a blockchain (e.g., crypto-currency). Unlike traditional blockchain crypto-currency protocols based on lower level hop-to-hop networking protocols, the disclosed technology processes data in parallel without addresses or hops by decoupling applications from processing hardware and networks, thereby attaining performance while maintaining scalability and reliability incrementally without infrastructure size limitations. Accordingly, the disclosed technology enables quantum-class cloud computing.
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Feldman, Arthur M.
Tilley, Douglas G.
Zhu, Weizhong
Khalili, Kamel
Koch, Walter J.
Abrégé
Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
88.
System and method for distributed dual-function radar-communication
Temple University—Of The Commonwealth System of Higher Education (USA)
Governemnt of the United States, as represented by the Secretary of the Air Force (USA)
Inventeur(s)
Ahmed, Ammar
Zhang, Yimin Daniel
Himed, Braham
Abrégé
A system for distributed dual-function radar-communication comprises a plurality of dual-function radar transmitters positioned within a region of interest, each configured to transmit at least one radar waveform, with each transmitter for having a minimum transmit power, a maximum transmit power, and a working transmit power, a plurality of radar receivers positioned within the region of interest, each configured to receive the radar waveforms, at least one controller communicatively connected to at least one connected transmitter of the plurality of dual-function radar transmitters, configured to calculate a vector of transmit power values for the plurality of dual-function radar transmitters. A method of transmitting a radar waveform is also disclosed.
G01S 7/00 - Détails des systèmes correspondant aux groupes , ,
G01S 13/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes radio, p. ex. systèmes radarSystèmes analogues utilisant la réflexion ou la reradiation d'ondes dont la nature ou la longueur d'onde sont sans importance ou non spécifiées
89.
METHOD OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF VITAMIN D DEFICIENCY AND VITAMIN D IMBALANCE AND DISEASES AND DISORDERS ASSOCIATED THEREOF
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Wilson, Robin Taylor
Abrégé
The present invention relates to compositions and methods relating to biomarkers (e.g., calcitriol (i.e., 1,25(OH)2D3) to 24,25-dihydroxyvitamin D3 (i.e., 24,25(OH)2D3) to calcifediol (i.e., 25(OH)D3) proportion ratio (C24CPR)) that can be used for detection and treatment assessment of vitamin D deficiency or vitamin D imbalance and/or diseases or disorders associated with vitamin D deficiency or vitamin D imbalance, such as cancer, in a subject in need thereof. The present invention also provides methods of diagnosing vitamin D deficiency or vitamin D imbalance and/or diseases or disorders associated with vitamin D deficiency or vitamin D imbalance and distinguishing between different types of diseases or disorders associated with vitamin D deficiency or vitamin D imbalance (e.g., cancer vs autoimmune disease or disorder).
G01N 33/82 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des vitamines
A61K 31/592 - Dérivés du 9,10-séco-ergostane, p. ex. ergocalciférol, vitamine D2
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
90.
RETROGRADE CORONARY VENOUS OR SINUS ADMINISTRATION OF THERAPEUTICS
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
RENOVACOR, INC. (USA)
Inventeur(s)
Feldman, Arthur M.
Myers, Valerie
Bologna, Marcia
Abrégé
The invention provides methods of delivering a therapeutic to the heart. In one embodiment, a method includes administering to a subject the therapeutic via retrograde coronary venous or sinus delivery thereby delivering the therapeutic to the heart.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
RENOVACOR, INC. (USA)
Inventeur(s)
Feldman, Arthur M.
Myers, Valerie
Bologna, Marcia
Abrégé
The invention provides methods of delivering a therapeutic to the heart. In one embodiment, a method includes administering to a subject the therapeutic via retrograde coronary venous or sinus delivery thereby delivering the therapeutic to the heart.
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Schafmeister, Christian
Northrup, Justin
Abrégé
This invention provides unnatural amino acids as well as amino acid sequences, foldamers, macrocycles, and formulations comprising said unnatural amino acids. In one aspect of the invention, the unnatural amino acids or the formulation thereof are used to mimic natural amino acids or the formulations thereof in a subject in need thereof.
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Won, Chang-Hee
Abrégé
A mobile-platform imaging device uses compression of the target region to generate an image of an object. A tactile sensor has an optical waveguide with a flexible, transparent first layer. Light is directed into the waveguide. Light is scattered out of the first layer when the first layer is deformed. The first layer is deformed by the tactile sensor being pressed against the object. A force sensor detects a force pressing the tactile sensor against the object and outputs corresponding force information. A first communication unit receives the force information from the force sensor. A receptacle holds a mobile device with a second communication unit and an imager that can generate image information using light scattered out of the first layer. The first communication unit communicates with the second communication unit and the mobile device communicates with an external network.
G02B 6/10 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 90/30 - Dispositifs pour éclairer une zone chirurgicale, les dispositifs ayant une corrélation avec d’autres dispositifs chirurgicaux ou avec une intervention chirurgicale
G01N 3/08 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique par application d'efforts permanents de traction ou de compression
G01N 19/00 - Recherche sur les matériaux par des procédés mécaniques
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Kuenstner, John Todd
Potula, Raghava
Abrégé
The present invention generally relates to kits for detecting Mycobacterium avium subspecies paratuberculosis (MAP) infection and biomarkers correlated with MAP-associated diseases or disorders. The present method also relates to methods of diagnosing a subject with a MAP-associated autoimmune disease or disorder and/or determining the treatment course of a subject diagnosed with a MAP-associated autoimmune disease or disorder.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
95.
OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Hu, Wenhui
Abrégé
A novel, small (21-mer oligonucleotide) and unique cz's-regulatory coding motif can greatly enhance the production of a variety of different types of proteins ranging from viral transcripts/proteins, endogenous gene products, vaccines, antibodies to engineered recombinant proteins in mammalian cells. The combination of novel peptide tag(s) having specified short amino acid sequences or derivatives thereof and the untranslated region (UTR) of viruses (snUTR) enhanced production of tagged proteins, including viral transcripts/proteins, endogenous gene products, vaccine, antibody, engineered recombinant proteins in a cell both in vitro, ex vivo and in vivo.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
96.
OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Hu, Wenhui
Abrégé
A novel, small (21-mer oligonucleotide) and unique cz's-regulatory coding motif can greatly enhance the production of a variety of different types of proteins ranging from viral transcripts/proteins, endogenous gene products, vaccines, antibodies to engineered recombinant proteins in mammalian cells. The combination of novel peptide tag(s) having specified short amino acid sequences or derivatives thereof and the untranslated region (UTR) of viruses (snUTR) enhanced production of tagged proteins, including viral transcripts/proteins, endogenous gene products, vaccine, antibody, engineered recombinant proteins in a cell both in vitro, ex vivo and in vivo.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Mohsin, Sadia
Houser, Steven
Kubo, Hajime
Abrégé
Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Temple University-Of The Commonwealth System of Higher Education (USA)
Inventeur(s)
Yang, Weidong
Ruba, Andrew
Abrégé
The present invention discloses a photon enhancement apparatus comprising a reflective component and 4f coherent imaging system, which increases a photon collection efficiency. The present invention also provides a microscope comprising said photon enhancement apparatus and methods of improving photon collection efficiency, signal-to-noise ratio, and/or optical resolution using the said photon enhancement apparatus.
Temple University - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Khalili, Kamel
Hu, Wenhui
Wollebo, Hassen
Abrégé
The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising an CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Khalili, Kamel
Kaminski, Rafal
Abrégé
Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.